
Emcure Pharmaceuticals Share Price Target 2027: 20.5% Upside to Rs 2,830, Bull Case Rs 3,390
Emcure Pharmaceuticals share price Rs 2,349.20 (16 November 2026). Base target Rs 2,830, bull Rs 3,390, downside risk Rs 1,887. PE 40.95. 52W range Rs 1,312.30 to Rs 2,429.90.
Updated: 16 Nov 2026 • 2:00 pm
Posted by:

Quick Answer
The Emcure Pharmaceuticals share price target for 2027 is Rs 2,830, about 20.5% above the current price of Rs 2,349.20. The bull case is Rs 3,390, and the downside risk level, which is not a target, is Rs 1,887. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 33.1%, with the stock holding its PE of 40.95. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Emcure Pharmaceuticals target price for 2027 should start with where the stock sits today. At Rs 2,349.20 on 16 November 2026, it is 3.3% below its 52-week high of Rs 2,429.90 and 79.0% above its 52-week low of Rs 1,312.30. That range spans 85% from low to high, so the entry point matters as much as the Emcure Pharmaceuticals price forecast itself.
This article builds the Emcure Pharmaceuticals share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Emcure Pharmaceuticals Stock Analysis: Company Overview and Key Stats
Emcure Pharmaceuticals (NSE: EMCURE) has a market capitalisation of Rs 44,746 crore. In FY26 it reported revenue of Rs 9,335 crore and net profit of Rs 941.27 crore. The table collects the figures the Emcure Pharmaceuticals share price target is built on.
| Metric | Value |
|---|---|
| Company | Emcure Pharmaceuticals |
| NSE Ticker | EMCURE |
| CMP (16 November 2026) | Rs 2,349.20 |
| 52-Week High | Rs 2,429.90 |
| 52-Week Low | Rs 1,312.30 |
| Market Cap | Rs 44,746 crore |
| PE Ratio (TTM) | 40.95 |
| Industry PE | 40.65 |
| Price to Book | 8.37 |
| Return on Equity | 20.46% |
| Debt to Equity | 0.34 |
| EPS (TTM) | Rs 57.60 |
| Dividend Yield | 0.15% |
| 12-Month Base Target | Rs 2,830 |
| Bull Case | Rs 3,390 |
| Downside Risk Level (not a target) | Rs 1,887 |
Why Is Emcure Pharmaceuticals Share Price Target Set at Rs 2,830 for 2027?
The arithmetic is short. Trailing EPS of Rs 57.60 grown for one year gives a forward EPS estimate of Rs 69.12, and multiplying it by the unchanged PE of 40.95 gives the Rs 2,830 base-case Emcure Pharmaceuticals stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Emcure Pharmaceuticals Target Price: Five Years of Results
Emcure Pharmaceuticals grew revenue from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew more slowly, from Rs 702.56 crore to Rs 941.27 crore (7.6% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 5,918.86 | 702.56 | 36.62 | 3.00 |
| FY23 | 6,031.72 | 561.85 | 29.42 | 2.00 |
| FY24 | 6,715.24 | 527.58 | 27.54 | 2.00 |
| FY25 | 7,968.78 | 707.47 | 36.43 | 3.00 |
| FY26 | 9,335.01 | 941.27 | 48.77 | 3.60 |
FY26 revenue growth was 17.1%, faster than the four-year average of 12.1%, and net profit moved up 33.0%. EPS rose from Rs 27.54 in FY24 to Rs 48.77 in FY26. The FY27 outlook for the Emcure Pharmaceuticals price target depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Emcure Pharmaceuticals converted 10.1% of FY26 revenue into net profit, against 8.9% in FY25, within a five-year range of 7.9% to 11.9%. EBITDA margin was 19.8% in FY26 versus 19.2% in FY25.
In the September 2026 quarter, revenue was Rs 2,824 crore, up 24.2% from the same quarter a year earlier, while net profit of Rs 325.07 crore was up 29.3%. EBITDA came in at Rs 591.09 crore, up 23.5% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Emcure Pharmaceuticals stock target holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.34, and shareholders' equity grew from Rs 2,114 crore in FY22 to Rs 4,977 crore in FY26. Operating cash flow in FY26 was Rs 943.55 crore against capital expenditure of Rs 547.69 crore, leaving free cash flow of Rs 395.86 crore, or 0.9% of the current market capitalisation. In FY25 free cash flow was Rs 444.78 crore.
Valuation Check for the Emcure Pharmaceuticals Stock Target: PE, Price to Book and ROE
At a PE of 40.95 against an industry PE of 40.65, Emcure Pharmaceuticals trades in line with its industry. Price to book is 8.37 on a book value of Rs 281.69 per share, and return on equity is 20.46%. A PE of 40.95 equals an earnings yield of 2.4%, and the FY26 dividend of Rs 3.60 per share gives a yield of 0.15%.
Shareholding Pattern and Institutional Holding
Promoters held 77.82% of Emcure Pharmaceuticals in September 2026, and promoter holding has stayed near 77.82% since September 2025. Foreign institutional investors (FII) held 4.94% and domestic institutions (DII) held 8.49%, which puts total institutional holding at 13.43%. FII holding rose from 3.29% in September 2025 to 4.94% in September 2026. Public shareholders own the remaining 8.75%.
Emcure Pharmaceuticals Share Price Targets for the Short Term and 12 Months
Short Term Emcure Pharmaceuticals Stock Target Levels: Technical Setup
At Rs 2,349.20 on 16 November 2026, Emcure Pharmaceuticals trades above its 50-day simple moving average of Rs 1,965.36 and above its 200-day exponential moving average of Rs 1,789.32. The 14-day RSI reads 83.3, which is overbought territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 2,429.90 (52-week high) and the nearest support is Rs 1,965.36 (50-day simple moving average). A sustained move above Rs 2,429.90 would improve the short-term setup, while a close below Rs 1,965.36 would shift attention to the next support.
12 Month Emcure Pharmaceuticals Target Price for 2027
The 12-month target of Rs 2,830 means a move of 20.5% up from Rs 2,349.20 over the next 12 months. It would also push the stock above its 52-week high of Rs 2,429.90. Anyone checking the Emcure Pharmaceuticals share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Emcure Pharmaceuticals Target Price
| EPS Growth | PE 32.76 | PE 40.95 | PE 47.09 |
|---|---|---|---|
| 0.0% (EPS Rs 57.60) | Rs 1,887 | Rs 2,359 | Rs 2,712 |
| 20.0% (EPS Rs 69.12) | Rs 2,264 | Rs 2,830 | Rs 3,255 |
| 25.0% (EPS Rs 72.00) | Rs 2,359 | Rs 2,948 | Rs 3,390 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Emcure Pharmaceuticals price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Emcure Pharmaceuticals Stock Target in 2027
Bull Case Rs 3,390
The bull case Emcure Pharmaceuticals price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 72.00, and a PE multiple that rises 15% to 47.09. That gives Rs 3,390, 44.3% above the current price and above the 52-week high of Rs 2,429.90, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,887
The downside risk level is not a target. It assumes EPS stays flat at Rs 57.60 and the PE falls 20% to 32.76. That gives Rs 1,887, 19.7% below the current price and above the 52-week low of Rs 1,312.30.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 47.09 | Rs 3,390 | +44.3% |
| Base Case | 20.0% | 40.95 | Rs 2,830 | +20.5% |
| Downside Risk | 0.0% | 32.76 | Rs 1,887 | -19.7% |
Key Risks to the Emcure Pharmaceuticals Target Price for 2027
Growth Slowdown Risk for the Emcure Pharmaceuticals Price Target
Revenue in the September 2026 quarter was up 24.2% year on year, and FY26 revenue growth was 17.1%. If growth slows from here, the EPS estimate behind the Emcure Pharmaceuticals stock target will need revising.
Liquidity and Size Risk
Emcure Pharmaceuticals has a market capitalisation of Rs 44,746 crore. Institutional holding is 13.43%, and promoters hold 77.82%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 10.1% in FY26, so a small slip in costs moves profit noticeably. At a PE of 40.95 versus an industry PE of 40.65, a de-rating toward the downside-risk PE of 32.76 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 83.3 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time.
How to Invest in Emcure Pharmaceuticals
Start with the live price and volume. Any Emcure Pharmaceuticals share price target is only as current as the data behind it, and the data here is as of 16 November 2026, so refresh the Rs 2,349.20 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Emcure Pharmaceuticals' PE, ROE, debt and shareholding in one place.
Check Emcure Pharmaceuticals fundamentals on the Univest Screener
Then compare the three Emcure Pharmaceuticals target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Emcure Pharmaceuticals live price and get daily stock recommendations.
Conclusion
The Emcure Pharmaceuticals share price target for 2027 is Rs 2,830 in the base case, with Rs 3,390 as the bull case. The support for that view is arithmetic you can check: EPS grew 33.1% a year over FY24 to FY26, and the stock trades at a PE of 40.95. The risks are equally concrete, including a net margin of just 10.1% that leaves profit sensitive to costs and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Emcure Pharmaceuticals price target, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Emcure Pharmaceuticals Share Price Target 2027
What is the Emcure Pharmaceuticals share price target for 2027?
Ans. The base-case Emcure Pharmaceuticals share price target for 2027 is Rs 2,830, which is 20.5% above the price of Rs 2,349.20 on 16 November 2026. The bull case is Rs 3,390 and the downside risk level, which is not a target, is Rs 1,887. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Emcure Pharmaceuticals share price today?
Ans. As of 16 November 2026, 1:32 PM IST, Emcure Pharmaceuticals (NSE: EMCURE) trades at Rs 2,349.20, down 0.53% on the day. That is 3.3% below the 52-week high of Rs 2,429.90 and 79.0% above the 52-week low of Rs 1,312.30. The market capitalisation of Rs 44,746 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Emcure Pharmaceuticals a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 33.1% a year over FY24 to FY26 and the base case implies 20.5% upside; on the cautious side, the net margin is a thin 10.1%, and the downside risk level of Rs 1,887 is 20% below the current price. Whether Emcure Pharmaceuticals fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Emcure Pharmaceuticals shares?
Ans. The bull case in the Emcure Pharmaceuticals share price target for 2027 is Rs 3,390, which assumes 25.0% EPS growth and a PE of 47.09, a 15% re-rating from today's multiple. That is 44.3% above the current price and above the 52-week high of Rs 2,429.90, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 1,887, which assumes flat EPS and a PE of 32.76, 20% lower than today. It sits 19.7% below the current price and above the 52-week low of Rs 1,312.30, and it marks a risk to watch, not a target.
What are the main risks to the Emcure Pharmaceuticals price target?
Ans. Four risks matter most for the Emcure Pharmaceuticals share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 44,746 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 32.76 would cut the price even if earnings hold.
What is the PE ratio of Emcure Pharmaceuticals and how does it compare with the industry?
Ans. The PE ratio of Emcure Pharmaceuticals is 40.95, against an industry PE of 40.65, which is a level close to the industry. Price to book is 8.37 and return on equity is 20.46%, and the PE equals an earnings yield of 2.4%. The base case holds the PE unchanged, so the Emcure Pharmaceuticals share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Emcure Pharmaceuticals, and what is the promoter holding?
Ans. Promoters held 77.82% of Emcure Pharmaceuticals in September 2026. FII held 4.94%, DII held 8.49% and the public held 8.75%. Together the two institutional groups hold 13.43%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Emcure Pharmaceuticals' latest quarterly results?
Ans. In the September 2026 quarter, Emcure Pharmaceuticals reported revenue of Rs 2,824 crore (up 24.2% year on year) and net profit of Rs 325.07 crore (up 29.3%). For comparison, FY26 full-year revenue growth was 17.1% and net profit moved up 33.0%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.
Recent Articles

SEBI F&O Study FY22 to FY26: What the Data Says About Retail Traders' Losses in India
16 November 2026

How to Read a Balance Sheet: Assets, Liabilities, Equity and the Key Ratios Every Share Investor Should Check Before Buying
16 November 2026

DuPont Analysis Explained: Breaking Return on Equity Into Margin, Asset Turnover and Equity Multiplier With a Worked Example
16 November 2026

Price to Book Ratio Explained: How to Calculate P/B, What a Low or High PB Means and Why Banks Are Valued This Way
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
SEBI F&O Study FY22 to FY26: What the Data Says About Retail Traders' Losses in India
How to Read a Balance Sheet: Assets, Liabilities, Equity and the Key Ratios Every Share Investor Should Check Before Buying
DuPont Analysis Explained: Breaking Return on Equity Into Margin, Asset Turnover and Equity Multiplier With a Worked Example
Price to Book Ratio Explained: How to Calculate P/B, What a Low or High PB Means and Why Banks Are Valued This Way
Repo Rate and Stock Market: How RBI Rate Decisions Move Banks, Real Estate, Autos and the Index, and What Investors Should Watch
Popular this week
REIT and InvIT Explained: How They Earn, Distribution Rules, Taxation, Risks and How They Differ From Direct Property Investing

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





